Sandoz announced the European launch of its Pyzchiva (ustekinumab) autoinjector. This is the first ustekinumab biosimilar in Europe commercially available in an autoinjector. Developed and registered by Samsung… read more.
GSK plc announced that the FDA has approved Nucala (mepolizumab) as an add-on maintenance treatment for adult patients with inadequately controlled COPD and an eosinophilic phenotype. FDA’s approval… read more.
Roche announced the introduction of its innovative Chest Pain Triage algorithm as part of the navify Algorithm Suite. This groundbreaking algorithm is designed to more quickly and accurately… read more.
Johnson & Johnson MedTech, a leader in neurovascular care, announced today its upcoming data presentations and onsite activities at the 2025 Society of NeuroInterventional Surgery (SNIS) 22nd Annual Meeting &… read more.
Celltrion announced that the FDA has approved Avtozma (CT-P47, tocilizumab-anoh) in both an intravenous (IV) and subcutaneous (SC) formulation as a biosimilar to Actemra. Avtozma is indicated for… read more.
Cytokinetics, Incorporated (announced five presentations related to aficamten at the European Society of Cardiology Congress 2025 taking place in Madrid, Spain from August 29, 2025 – September 1,… read more.
The EMA has recommended granting a marketing authorisation in the European Union (EU) for Tepezza (teprotumumab), for the treatment of adults with moderate to severe thyroid eye disease…. read more.
The Committee for Medicinal Products for Human Use (CHMP) of the EMA adopted a positive opinion, recommending a change to the terms of the marketing authorisation for Bosulif…. read more.
OPKO Health, Inc and Entera Bio Ltd announced that their abstract “First-in-Class Oral GLP-2 Analog for Treatment of Short Bowel Syndrome” has been selected for a poster presentation… read more.
Johnson & Johnson announced new data from the Tremfya (guselkumab) Phase III QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis (UC). Data from the… read more.
The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has approved Eylea 8 mg (aflibercept 8 mg) for the treatment of neovascular (wet) age-related… read more.
Alnylam Pharmaceuticals Inc. announced that the Committee for Medicinal Products for Human Use (CHMP) of the EMA has adopted a positive opinion recommending approval of its RNAi therapeutic… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
